Shield Meter (MVP)
Educational visualization of tumor “shields” (NADPH, GSH, Trx, NRF2). Not medical advice.
Patient (for unit conversions)
BSA (Mosteller): 1.82 m²
Select cancer type
Empirically high redox buffering; consider NADPH & GSH-first modeling.
Shields
NADPH supply
78
PPP, malic enzyme, IDH1/IDH2, folate
Glutathione system (GSH)
82
xCT/SLC7A11, GCLC/GCLM, GPX4
Thioredoxin system (Trx)
75
TXN, TXNRD1/2, PRDXs
NRF2/KEAP1 axis
70
Global antioxidant program
Total Shield Score
78
Very high
Evidence (directional): NADPH supply (PPP, ME1/IDH1/2) powers GSH/Trx recycling; xCT/SLC7A11 elevates GSH; TXNRD1 boosts Trx; NRF2 upregulates antioxidant genes. Auranofin inhibits TrxR; Oroxylin A & DCA can pressure PPP; BSO and Piperlongumine strain GSH/Trx; Sulfasalazine blocks xCT. Timing of NRF2 activators matters.
Biomarkers & Features
Medications & Agents (modeling only)
No agents added yet. Choose one above to simulate effects.
Modeling only. Not medical advice. Ranges are placeholders pending evidence calibration. Effects vary by context, genotype, timing, and combinations.